- Home
- ADAP vs IRIX Comparison
ADAP vs IRIX Comparison
Compare ADAP & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- IRIX
- Stock Information
- Founded
- ADAP 2008
- IRIX 1989
- Country
- ADAP United Kingdom
- IRIX United States
- Employees
- ADAP N/A
- IRIX N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ADAP Health Care
- IRIX Health Care
- Exchange
- ADAP Nasdaq
- IRIX Nasdaq
- Market Cap
- ADAP 21.3M
- IRIX 20.2M
- IPO Year
- ADAP 2015
- IRIX 1996
- Fundamental
- Price
- ADAP $0.14
- IRIX $1.10
- Analyst Decision
- ADAP Hold
- IRIX
- Analyst Count
- ADAP 6
- IRIX 0
- Target Price
- ADAP $1.02
- IRIX N/A
- AVG Volume (30 Days)
- ADAP 139.0M
- IRIX 65.6K
- Earning Date
- ADAP 11-12-2025
- IRIX 11-11-2025
- Dividend Yield
- ADAP N/A
- IRIX N/A
- EPS Growth
- ADAP N/A
- IRIX N/A
- EPS
- ADAP N/A
- IRIX N/A
- Revenue
- ADAP $65,084,999.00
- IRIX $49,744,000.00
- Revenue This Year
- ADAP N/A
- IRIX $9.61
- Revenue Next Year
- ADAP $24.70
- IRIX N/A
- P/E Ratio
- ADAP N/A
- IRIX N/A
- Revenue Growth
- ADAP N/A
- IRIX 0.09
- 52 Week Low
- ADAP $0.04
- IRIX $0.78
- 52 Week High
- ADAP $0.96
- IRIX $1.95
- Technical
- Relative Strength Index (RSI)
- ADAP 56.57
- IRIX 39.76
- Support Level
- ADAP $0.12
- IRIX $1.09
- Resistance Level
- ADAP $0.16
- IRIX $1.23
- Average True Range (ATR)
- ADAP 0.03
- IRIX 0.08
- MACD
- ADAP 0.00
- IRIX -0.01
- Stochastic Oscillator
- ADAP 39.87
- IRIX 16.18
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.